This article is more than 5 years old. Information may no longer be current.

Alimera reports net loss for fourth quarter, full year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported a GAAP net loss of $14.8 million, or $0.47 per common share, for the fourth quarter of 2013, compared with a GAAP net loss of $5.3 million, or $0.17 per common share, for the fourth quarter of 2012, according to a press release.

The loss was attributed to an increase in the fair value of Alimera’s derivative warrant liability, a non-cash unrealized foreign currency gain and inventory issues.

For the full year, GAAP net loss was $51.2 million, or $1.62 per common share, compared with $19.8 million, or $0.63 per common share, for 2012.

Quarterly non-GAAP adjusted net loss was $7.5 million, or $0.24 per common share, compared with a non-GAAP adjusted net loss of $8.4 million, or $0.27 per common share, in the prior year’s quarter.

Net revenue for the quarter was $935,000, compared with $758,000 the prior year.